Gyre Therapeutics (GYRE) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.40% |
| Dec 31, 2025 | -21.35% |
| Sep 30, 2025 | 16.09% |
| Jun 30, 2025 | 31.51% |
| Mar 31, 2025 | -43.44% |
| Dec 31, 2024 | 13.07% |
| Sep 30, 2024 | -15.55% |
| Jun 30, 2024 | -12.14% |
| Mar 31, 2024 | 9.88% |
| Dec 31, 2023 | 43.88% |
| Sep 30, 2023 | 15.62% |
| Jun 30, 2023 | 38.54% |
| Mar 31, 2023 | -15.40% |
| Dec 31, 2022 | -60.54% |
| Sep 30, 2022 | -19.25% |
| Jun 30, 2022 | 29.85% |
| Mar 31, 2022 | -31.07% |
| Dec 31, 2021 | -77.54% |
| Sep 30, 2021 | -48.31% |
| Jun 30, 2021 | -0.04% |
| Mar 31, 2021 | 52.27% |
| Dec 31, 2020 | -1.95% |
| Sep 30, 2020 | -29.57% |
| Jun 30, 2020 | -117.61% |
| Mar 31, 2020 | 153.53% |
| Dec 31, 2019 | -30.01% |
| Sep 30, 2019 | -13.85% |
| Jun 30, 2019 | -36.43% |
| Mar 31, 2019 | 8.10% |
| Dec 31, 2018 | -17.50% |
| Sep 30, 2018 | -51.86% |
| Jun 30, 2018 | -63.72% |
| Mar 31, 2018 | 60.46% |
| Dec 31, 2017 | -5.13% |
| Sep 30, 2017 | -39.63% |
| Jun 30, 2017 | 21.48% |
| Mar 31, 2017 | 33.26% |
| Dec 31, 2016 | 15.33% |
| Sep 30, 2016 | 44.30% |
| Jun 30, 2016 | -18.34% |
| Mar 31, 2016 | 20.62% |
| Dec 31, 2015 | 18.13% |
| Sep 30, 2015 | 20.87% |